UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 90

Sortiert nach

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-07, Vol.373 (2), p.123-135

2015

Link zum Volltext

Verfügbarkeit prüfen

C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy

Scientific reports, 2024-06, Vol.14 (1), p.13765-12, Article 13765

2024

Link zum Volltext

Verfügbarkeit prüfen

Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT

Scientific reports, 2022-10, Vol.12 (1), p.17511-17511, Article 17511

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma

Scientific reports, 2020-10, Vol.10 (1), p.18677, Article 18677

2020

Link zum Volltext

Verfügbarkeit prüfen

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

BMC cancer, 2019-01, Vol.19 (1), p.108-12, Article 108

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-12, Vol.29 (34), p.4574-4580

2011

Link zum Volltext

Verfügbarkeit prüfen

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2523-2529

2009

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5407-5415

2008

Link zum Volltext

Verfügbarkeit prüfen

Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment

Radiation oncology (London, England), 2022-07, Vol.17 (1), p.1-126, Article 126

2022

Link zum Volltext

Verfügbarkeit prüfen

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

BMC cancer, 2018-02, Vol.18 (1), p.135-135, Article 135

2018

Link zum Volltext

Verfügbarkeit prüfen

68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study

The Journal of nuclear medicine (1978), 2023-10, Vol.64 (10), p.1540-1549

2023

Link zum Volltext

Verfügbarkeit prüfen

Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

Journal of thoracic oncology, 2013-03, Vol.8 (3), p.373-384

2013

Link zum Volltext

Verfügbarkeit prüfen

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

Journal of thoracic oncology, 2015-11, Vol.10 (11), p.1515-1522

2015

Link zum Volltext

Verfügbarkeit prüfen

History Can Teach Us Something: Angiogenesis Inhibition Revisited

Journal of thoracic oncology, 2024-06, Vol.19 (6), p.849-851

2024

Link zum Volltext

Verfügbarkeit prüfen

Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition

Radiation oncology (London, England), 2021-09, Vol.16 (1), p.1-176, Article 176

2021

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4007-4014

2015

Link zum Volltext

Verfügbarkeit prüfen

Too Good to be True?

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.507-508

2021

Link zum Volltext

Verfügbarkeit prüfen

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

Investigational new drugs, 2014-02, Vol.32 (1), p.123-134

2014

Link zum Volltext

Verfügbarkeit prüfen

N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard

EJNMMI research, 2021-07, Vol.11 (1), p.68-68, Article 68

2021

Link zum Volltext

Verfügbarkeit prüfen

Neutrophils Activate Tumoral CORTACTIN to Enhance Progression of Orohypopharynx Carcinoma

Frontiers in immunology, 2013-01, Vol.4, p.33-33

2013

Link zum Volltext

Verfügbarkeit prüfen

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.54-64

2017

Link zum Volltext

Verfügbarkeit prüfen

A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient's Suitability for Immune Checkpoint Inhibition

Cancer management and research, 2020-01, Vol.12, p.7881-7890

2020

Link zum Volltext

Verfügbarkeit prüfen

Aktueller Stand der Diagnostik und Therapie des nichtkleinzelligen Lungenkarzinoms (NSCLC) im Stadium III

Der Onkologe, 2018-12, Vol.24 (12), p.974-982

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 90

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(89)

Publikationsform

Artikel
(90)

Sprache

Englisch
(86)
Japanisch
(16)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(65)
Oncology
(60)
Humans
(55)
Lung Neoplasms - Pathology
(32)
Respiratory System
(29)
Lung Cancer
(28)
Female
(27)
Male
(26)
Neoplasm Staging
(23)
Middle Aged
(22)
Prognosis
(22)
Aged
(21)
Carcinoma, Non-Small-Cell Lung - Pathology
(18)
Adult
(16)
Lung Neoplasms - Drug Therapy
(16)
Tumors
(16)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(14)
Biological And Medical Sciences
(11)
Lung Neoplasms - Classification
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy

Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT

Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III Disease

Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study

Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

History Can Teach Us Something: Angiogenesis Inhibition Revisited

Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Too Good to be True?

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard

Neutrophils Activate Tumoral CORTACTIN to Enhance Progression of Orohypopharynx Carcinoma

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer

A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient's Suitability for Immune Checkpoint Inhibition

Aktueller Stand der Diagnostik und Therapie des nichtkleinzelligen Lungenkarzinoms (NSCLC) im Stadium III

Aktive Filter

Suchergebnisse filtern